KT-579

KT-579 is a first-in-class, potent, selective oral small molecule degrader of interferon regulatory factor 5 (IRF5), developed by Kymera Therapeutics. IRF5 is a transcription factor that acts as a master regulator of innate and adaptive immune responses, controlling pro-inflammatory cytokines (such as TNFα, IL-6, IL-12, IL-23), B cell activation and autoantibody production, and Type I interferon signaling. Historically considered "undruggable," IRF5 is selectively expressed in dendritic cells, monocytes, macrophages and B cells. By degrading IRF5 rather than inhibiting downstream pathways or cytokines directly, KT-579 aims to block disease-specific immune dysregulation while sparing normal immune function. In preclinical studies across human primary cells and animal models for lupus erythematosus and rheumatoid arthritis (RA), KT-579 demonstrated robust degradation (>90%) of IRF5 in relevant tissues at low oral doses with high selectivity over other proteins—including other IRFs—and showed efficacy equal to or greater than current standards of care including biologics. Safety studies revealed no adverse effects at concentrations up to 200-fold above projected efficacious levels. The drug is currently in IND-enabling studies with Phase 1 clinical trials planned for early 2026[1][2][3][4][5][6].